Roche invests 120 million Swiss francs in new production facilities at Basel

Today Roche announced plans to invest a total of 120 million Swiss francs in the construction of new production facilities in Building 50, an existing building at its Basel site. Eighty five million francs will go into a new facility for chemically manufactured medicines, while the remaining 35 million francs will be invested in the expansion and refitting of an existing multipurpose unit for the production of investigational drugs and medicines that are already on the market.

Matthias M. Baltisberger, Head of Basel/Kaiseraugst Site, commented: “This investment is an important step for our future. In developing these two new facilities, we are enhancing the site’s appeal and continuing to provide jobs for highly skilled technicians, scientists, engineers and quality specialists.”

Initial preparatory work has already started in Building 50. Production of the highly effective medicines is scheduled to start in the third quarter of 2016, while the flexible multipurpose unit, which can be rapidly adapted to changing production requirements, will enter service in June 2015.